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Summary. Monocarboxylate transporters (MCTs)
belong to a family of transporters, encoded by the SLC16
gene family, which is presently composed by 14
members, but only MCT1 to 4 have been biochemically
characterized. They have important functions in healthy
tissues, being involved in the transmembrane transport
of lactic acid and other monocarboxylic acids in human
cells. 
One of the recently recognized hallmarks of cancer
is altered metabolism, with high rates of glucose
consumption and consequent lactate production. To
maintain this metabolic phenotype, cancer cells
upregulate a series of plasma membrane proteins,
including MCTs. MCT1 and MCT4, in particular, play a
dual role in the maintenance of the metabolic phenotype
of tumour cells. On one hand, they facilitate the efflux of
lactate and, on the other hand, they contribute to the
preservation of the intracellular pH, by co-transporting a
proton. Thus, MCTs are attractive targets in cancer
therapy, especially in cancers with a hyper-glycolytic
and acid-resistant phenotype.
Recent evidence demonstrates that MCTs are
involved in cancer cell uptake of chemotherapeutic
agents, including 3-bromopyruvate. In this way MCTs
can act as “Trojan horses”, as their elevated expression
in cancer cells can mediate the entry of this
chemotherapeutic agent into the cells and selectively kill
cancer cells. As a result, MCTs will be mediators of
chemotherapeutic response, and their expression can be
used as a molecular marker to predict response to
chemotherapy. 
Key words: Monocarboxylate transporters, Cancer
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Introduction
Cancer is one of the leading causes of death
worldwide. Estimates from 2012 indicate that there are
annually about 14.1 million new cases of cancer and 8.2
million deaths due to the disease (Globocan, 2012).
Despite the progress in therapeutic optimization, there is
still much to be done in the cancer field and, thus,
understanding cancer cell physiological behaviour is
crucial for the discovery of new molecular targets and
novel drugs.
One of the emerging hallmarks of cancer is altered
metabolism, in which cancer cells exhibit high rates of
glucose consumption with concomitant lactate
production (Warburg, 1956; Hanahan and Weinberg,
2011). To maintain this metabolic phenotype, cancer
cells upregulate a series of proteins, including glycolytic
enzymes and pH regulators, including monocarboxylate
transporters (MCTs) that will facilitate the efflux of
lactate, co-transported with a proton.
MCTs have been described to be involved in the
transport of lactic acid and other monocarboxylic acids
in human cells, with important functions in healthy
tissues (Halestrap and Price, 1999; Halestrap, 2012;
Halestrap and Wilson, 2012). There is also evidence for
their role in cancer, given the increased lactic acid
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production by cancer cells (Froberg et al., 2001; Pinheiro
et al., 2012). Additionally, they have been described as
the transporters for chemotherapeutic agents like 3-
bromopyruvate (3-BP) (Cardaci et al., 2012; Queiros et
al., 2012; Matsumoto et al., 2013). Therefore, exploiting
MCTs either as specific molecular targets or drug
transporters in cancer cells can be of great clinical value,
opening new perspectives in cancer therapy.
The monocarboxylate transporter family
Monocarboxylate transporters (MCTs) belong to a
family of transporters, encoded by the SLC16 gene
family, which is presently composed by 14 members
(Pao et al., 1998; Halestrap and Meredith, 2004). MCT1-
4 have been demonstrated to facilitate the
transmembrane proton-linked transport of metabolically
important monocarboxylates such as lactate, pyruvate,
branched-chain oxoacids, and the ketone bodies
acetoacetate and β-hydroxybutyrate (Deuticke, 1982;
Yoon et al., 1997; Lin et al., 1998; Halestrap and Price,
1999; Dimmer et al., 2000). MCT1 has a ubiquitous
distribution in human tissues, with an important
expression in heart and muscle (Lin et al., 1998; Price et
al., 1998; Fishbein et al., 2002). This isoform has an
intermediate affinity for its substrates and is involved in
both uptake and efflux of monocarboxylates from cells.
MCT2 is considered a high affinity transporter, being
adapted to the uptake of monocarboxylates into cells
(Lin et al., 1998; Broer et al., 1999). This isoform shows
a more restricted tissue distribution (Lin et al., 1998;
Fishbein et al., 2002), being mostly found in tissues that
use lactate as a respiratory fuel, like brain (Fishbein et
al., 2002; Pierre et al., 2002) or cardiac and red skeletal
muscles (Juel, 1997; Halestrap, 2013), as well as kidney
and liver, where lactate is the major gluconeogenic
substrate (Garcia et al., 1995; Fishbein et al., 2002).
MCT3 has an even more restricted distribution, it has
been identified in the retinal pigment and choroid plexus
epithelia, and implicated in the efflux of lactate in the
retina (Philp et al., 1998; Bergersen et al., 1999). On the
other hand, MCT4 is known as a low affinity transporter
and has been observed particularly in highly glycolytic
tissues, such as white skeletal muscle fibers, astrocytes,
and white blood cells (Price et al., 1998; Wilson et al.,
1998; Dimmer et al., 2000), being associated with lactate
efflux (Wilson et al., 1998; Halestrap and Price, 1999).
Although isoforms 1-4 are the best characterized
isoforms over the years, the function of other MCT
isoforms is already known. For example, SLC16A10
gene encodes for an aromatic amino-acid transporter (T-
type amino-acid transporter 1, named TAT1) (Kim et al.,
2001) and MCT8 transports thyroid hormones (Friesema
et al., 2003, 2008), while MCT6 transports bumetanide,
but not L-lactic acid (Murakami et al., 2008). Although
the substrate for MCT12 is still unknown, recent studies
suggest that it may be involved in the establishment
and/or maintenance of homeostasis in the eye lens and
probably also in the kidney (Kloeckener-Gruissem et al.,
2008; Zuercher et al., 2010). The substrates of the
remaining members of the family (MCT5, MCT7,
MCT9, MCT11, MCT13 and MCT14) are still unknown.
Although the regulatory mechanisms of MCT
expression are not completely elucidated, evidence
indicates that MCTs are regulated at both transcriptional
and post-transcriptional levels. Importantly, hypoxia is
known to be a major regulator of MCT expression.
While there is some controversy around MCT1,
evidence for MCT4 upregulation by hypoxia is more
consistent (McClelland and Brooks, 2002; Ord et al.,
2005; Zhang et al., 2005; Ullah et al., 2006; Kay et al.,
2007; Sonveaux et al., 2008; Perez de Heredia et al.,
2010). Actually, MCT4 was described to be regulated by
the hypoxia inducible factor 1α (HIF-1α), a transcription
factor with a major role in the adaptation to hypoxia
(Ullah et al., 2006).
The association with ancillary proteins also appears
to be crucial for the functional regulation of MCTs, as
they are involved in trafficking and anchoring of
membrane proteins to specific cellular locations. In this
context, CD147 emerges as the major and best-studied
regulator of the expression of MCT isoforms 1, 3 and 4.
CD147, also known as basigin or EMMPRIN, belongs to
the immunoglobulin superfamily and is a broadly
distributed plasma membrane protein (Biswas et al.,
1995). CD147 was shown to specifically interact with
MCT1 and MCT4, but not MCT2, at the plasma
membrane (Kirk et al., 2000; Zhao et al., 2001; Ladanyi
et al., 2002; Wilson et al., 2002). Besides regulating
MCT membrane location (Makuc et al., 2004; Deora et
al., 2005; Gallagher et al., 2007; Baba et al., 2008; Su et
al., 2009), CD147 also regulates the expression of
MCT1, 3 and 4 (Philp et al., 2003; Gallagher et al.,
2007; Schneiderhan et al., 2009; Su et al., 2009), as well
as their activity as lactate transporters (Makuc et al.,
2004; Wilson et al., 2005). In turn, MCT1 and MCT4
were also demonstrated to regulate CD147 maturation
and trafficking to the plasma membrane (Deora et al.,
2005; Gallagher et al., 2007). In opposition, MCT2 was
found to preferentially interact with another member of
the immunoglobulin superfamily, gp70 (Huang et al.,
1990; Wilson et al., 2005). More recently, the
glycoprotein CD44 and its main ligand, hyaluronan,
were also identified to associate to the MCT1/MCT4/
CD147 complex in the context of drug resistance in
cancer therapy (Slomiany et al., 2009). Being also a
glycoprotein, one can hypothesize that CD44 could also
behave as a chaperone of these MCT isoforms.
The role of monocarboxylate transporters in cancer
Although the role of MCTs in physiological
homeostasis is well known in some tissues, less is
known about their role and clinical relevance in the
cancer context. 
Almost a century ago, Otto Warburg demonstrated
that cancer cells have a preference to use glycolysis for
energy production, independently of the levels of oxygen
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(Warburg, 1956), a phenomenon currently known as
“aerobic glycolysis” or “Warburg effect”. Despite the
flaws in Warburg’s original hypothesis (Wang et al.,
1976; Moreno-Sanchez et al., 2007), the observation of
increased glycolysis in cancer has been confirmed
repeatedly, being the rationale behind the whole-body
non-invasive 18F-fluorodeoxyglucose positron emission
tomography (FdG-PET) imaging technique. Although
much less energetically efficient than oxidative
phosphorylation, glycolysis provides several advantages
to cancer cells, such as allowing survival under
intermittent hypoxia (Gatenby and Gillies, 2004; Gillies
and Gatenby, 2007), being a source of anabolic
substrates essential for biosynthetic pathways (Gatenby
and Gillies, 2007; DeBerardinis et al., 2008) and
providing DNA protection from damage by oxygen
radicals produced during oxidative phosphorylation
(Kondoh et al., 2007). Additionally, the resulting
production of lactate gives rise to an acidic
microenvironment, providing a further competitive
advantage over normal cells (Gatenby et al., 2007;
Gillies and Gatenby, 2007), also facilitating cancer cell
invasion (Martinez-Zaguilan et al., 1996, Smallbone et
al., 2005, Rofstad et al., 2006). To avoid necrosis or
apoptosis induced by acid overproduction (Park et al.,
1999; Williams et al., 1999), cancer cells undergo a
series of adaptations, including upregulation of
membrane pH regulators (Gatenby and Gillies, 2004),
like the Na+/H+ exchanger 1 (NHE1), CAIX (carbonic
anhydrase 9), AE1 (anion exchanger 1) and MCTs,
MCT1 and MCT4 in particular. Here, MCTs play a dual
role; on one hand, they facilitate the efflux of lactate,
allowing the maintenance of the glycolytic phenotype
and, on the other hand, by co-transporting a proton along
with lactate, they contribute to the preservation of the
intracellular pH. Thus, MCTs appear as attractive targets
in cancer therapy, especially in cancers with the hyper-
glycolytic and acid-resistant phenotype.
Expression of MCTs in human tumours
Studies on the role of MCTs in cancer are becoming
more frequent over the years. The expression of MCTs
in human tumours has been recently reviewed by
Pinheiro and collaborators (Pinheiro et al., 2012).
Despite some controversies, MCTs appear to be
differentially expressed among solid tumours, a fact
most likely related to the different metabolic profiles of
tumours.
In colorectal carcinoma, there is controversy in the
literature around MCT expression. The first two reports
on colon carcinoma described downregulation of MCT1
expression (Ritzhaupt et al., 1998; Lambert et al., 2002),
but more recent evidence describes upregulation of both
MCT1 and MCT4 isoforms at the plasma membrane of
colorectal cancer, compared to the non-neoplastic
counterparts. Importantly, MCT2 and MCT4 were
strongly expressed in the cytoplasm of cancer cells
indicating a possible role in intracellular organelles such
as mitochondria (Koukourakis et al., 2006, Pinheiro et
al., 2008a). Also, plasma membrane MCT1 expression
was found to be associated with vascular invasion
(Pinheiro et al., 2008a). Although this association is easy
to understand, assuming the possible role of MCT1 in
lactate efflux, it needs further investigation.
Another tumour type with controversies on MCT
expression is breast cancer. A first report described that
SLC16A1 gene is silenced in 20% of breast cancer cases
due to promoter hypermethylation although the results
were not supported by mRNA or protein expression
analyses (Asada et al., 2003). In contrast, a more recent
study, comprising around 250 cases of breast carcinoma
cases, showed an overall increase of MCT1 expression.
MCT1 and its chaperone CD147 were associated with
the basal-like subtype of breast cancer and other poor
prognostic variables, such as high histological grade,
estrogen and progesterone receptor negativity and high
proliferation index, pointing at a role of MCT1/CD147
in breast carcinoma aggressiveness (Pinheiro et al.,
2010).
In tumours of the central nervous system, MCT1
expression was described to be much higher in
ependymomas, hemangioblastomas and high grade glial
neoplasms (anaplastic astrocytomas and glioblastoma
multiforme (GBM)), than in low-grade glial neoplasms
(oligodendrogliomas and astrocytomas) (Froberg, 2001).
In another study, MCT3 was predominantly found in
normal brain, whereas MCT1 and MCT2 were the major
isoforms present in GBM tumours. MCT4 was not
detected in any of the tumour tissues (Mathupala et al.,
2004). MCT1 expression in neuroblastoma was also high
and was associated with poor prognostic factors, such as
advanced disease, DNA diploid index, n-myc
amplification and high-risk clinical group (Fang et al.,
2006). In a more recent study, MCT1, MCT4, and
CD147 were described to be overexpressed at the plasma
membrane of glioblastoma cells, compared with diffuse
astrocytomas and non-neoplastic brain tissue (Miranda-
Goncalves et al., 2013).
In uterine cervix there is only one report showing a
significant increase in MCT1 and MCT4 expression
from pre-invasive to invasive squamous lesions and
from normal glandular epithelium to adenocarcinomas,
in a comprehensive series of squamous cell carcinomas
and adenocarcinomas (Pinheiro et al., 2008b).
MCT1, MCT2 and MCT4 were reported to be highly
expressed in gastro-intestinal stromal tumours (GISTs),
with some important associations with
clinicopathological data. CD147 expression was
associated with mutated KIT as well as a progressive
increase in Fletcher's Risk of Malignancy, while co-
expression of MCT1 with CD147 was associated with
low patient overall survival. These findings suggest that
the pair MCT1/CD147 is involved in GIST
aggressiveness, contributing to cancer cell metabolic
adaptations in GIST development and/or progression (de
Oliveira et al., 2012).
Finally, MCT downregulation was found in both
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gastric and prostate cancers (Pinheiro et al., 2009;
Pertega-Gomes et al., 2011). In gastric cancer, while
there were no differences in MCT1 and CD147
expressions between non-neoplastic mucosa and either
primary tumour or lymph-node metastasis, there was a
significant downregulation of MCT4 in the progression
to malignancy. However, the pair MCT1/CD147 was
associated with poor prognosis factors, such as advanced
gastric carcinoma, Lauren's intestinal type, TNM staging
and lymph-node metastasis (Pinheiro et al., 2009). In
prostate cancer, the first report on MCT expression
described both MCT1 and MCT4 upregulation in
prostate cancer tissues. The authors also suggested that
overexpression of CD147 and MCT4 is associated with
prostate cancer progression (Hao et al., 2010). A second
report described a significant increase in the cytoplasmic
expression of both MCT2 and MCT4, and a significant
decrease in both MCT1 and CD147 expression in
prostate tumour cells, when compared to normal tissue
(Pertega-Gomes et al., 2011). Associations were found
between MCT1, MCT4 and CD147 expressions and
poor prognostic markers. Importantly, MCT4 and
CD147 were associated with high PSA levels, Gleason
score and pT stage, as well as perineural invasion and
biochemical recurrence. More recently, the value of
MCT2 expression in the diagnosis of prostate cancer was
also explored. In this context, the pattern of expression
of MCT2 in normal prostate, precursor lesions and
prostate cancer was compared with that of alpha-
methylacyl-CoA racemase (AMACR), currently used in
prostate cancer diagnosis. In combination with AMACR
(positive marker) and p63 or 34βE12 (as negative
markers), MCT2 (positive marker) helped to improve the
diagnosis of prostate carcinoma, increasing the
sensitivity and specificity to detect prostate cancer
(Pertega-Gomes et al., 2013).
Besides playing an important role in cancer cells,
there have been increasing reports of MCT expression in
the tumour stroma. Actually, it appears that there is a
metabolic symbiosis between tumour and stroma cells,
where tumour cells produce lactate that will be used as
an energy substrate by stromal cells. The first evidence
was given by the group of Koukourakis and
collaborators, which demonstrated this metabolic
complementarity in colon cancer (Koukourakis et al.,
2006), The authors showed that cancer cells exhibit high
glucose transporter 1 (GLUT1), lactate dehydrogenase 5
(LDH5) and MCT1 expression, consistent with a
glycolytic phenotype, while cancer associated fibroblasts
express LDH1 and MCT1/MCT2 and low GLUT1,
consistent with a more oxidative phenotype. A similar
metabolic cooperation between lung cancer cells and
tumour-associated stroma was later described by the
same group, where MCTs were overexpressed in cancer
cells, with a weak expression of MCTs in the tumour-
associated stroma, while no expression was found in
normal lung (Koukourakis et al., 2007). More recently,
Lisanti and collaborators proposed a theory known as
“reverse Warburg effect”, in which the fibroblastic
tumour stroma feeds the epithelial cancer cells, in a host-
parasite relationship (Pavlides et al., 2009). Here, the
epithelial tumour cells would manipulate the normal
stroma to produce energy-rich metabolites to feed on
(Pavlides et al., 2009). 
MCTs as therapeutic targets in cancer
From the above described, it is easy to conjecture
that inhibition of MCT activity and/or expression will
certainly disturb cancer cell homeostasis, by interfering
with monocarboxylate transport and pH regulation.
Taking into account that there is up-regulation of MCTs
in several tumours, inhibition of these molecules can be
a useful strategy to explore in cancer treatment. 
The are several known classical MCT inhibitors,
which can be divided into three major categories: a)
bulky or aromatic monocarboxylates like α-cyano-4-
hydroxycinnamate (CHC); b) amphiphilic compounds
including bioflavonoids like quercetin and phloretin; and
c) stilbene-derived compounds such as 4,4-O-
diisothiocyanostilbene-2,20-disulphonate (DIDS) and
4,4-O-dibenzamidostilbene-2,2O-disulphonate (DBDS)
(Halestrap and Price, 1999). The sensitivities to the
different inhibitors vary among the MCT isoforms,
according to each isoform affinity for the substrates.
MCT2 is more sensitive to inhibition by CHC, DBDS
and DIDS than MCT1, but is insensitive to p-
chloromercuribenzene sulphonate (pCMBS) (Garcia et
al., 1995; Bonen et al., 2000). This difference in pCMBS
sensitivity results from the different accessory proteins
required for MCT1 and MCT2 activities, as the inhibitor
is now known to target CD147 (Wilson et al., 2005).
However, in opposition to MCT1, MCT3 is insensitive
to inhibition by CHC, pCMBS and phloretin (Grollman
et al., 2000). MCT4 exhibits a much lower sensitivity for
a wider range of inhibitors than MCT1 (Manning Fox et
al., 2000). 
However, these inhibitors are not specific and may
target other molecules. For example, the well-known
MCT inhibitor CHC, frequently used as an MCT1
inhibitor, also inhibits the mitochondrial pyruvate
transporter, as well as the anion exchanger isoform 1
(AE1) (Halestrap and Price, 1999). Quercetin and
phloretin also inhibit AE1 (Halestrap and Price, 1999),
efflux transporters including P-glycoprotein, multidrug
resistance protein 1/2 and breast cancer resistance
protein (Wang and Morris, 2007; Chen et al., 2010), as
well as some intracellular pathways including
phosphatidylinositol 3-kinase (PI3K)/Akt and
extracellular regulated kinase (ERK). 
In addition, other drugs have also been described as
inhibitors of lactate transport. For example, MCT4
activity is inhibited by a range of statins, which are
antihyperlipidemic drugs (Kobayashi et al., 2006).
Lonidamine was firstly described as hexokinase II
inhibitor (Floridi et al., 1981) but was also demonstrated
as an inhibitor of lactate transport (Ben-Yoseph et al.,
1998; Ben-Horin et al., 1995).
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Since the above compounds are not MCT specific,
the functional role of MCTs in cancer should be studied
using specific inhibitors. Thus AstraZeneca developed a
series of small molecule compounds like AR-C155858,
which promise to be MCT1 isoform specific and are
now under clinical trials (Porporato et al., 2011).
However, competition studies demonstrated that AR-
C155858 inhibits both MCT1 and MCT2, but not
MCT4, when expressed in oocytes (Ovens et al., 2010).
Over the last years, several authors have been
demonstrating the effect of MCT inhibition in cancer,
using both in vitro and in vivo models, which are
summarized below.
In vitro studies with cancer derived cells
The classical inhibitor CHC is described as
disturbing cancer cell homeostasis inducing cell death,
decreasing cell proliferation, invasion and other
important features in cancer cells through MCT
inhibition. In a study with glioma cells, treatment with
CHC prior to low-dose radiation exposure led to rapid
morphological changes, followed by apoptotic cell death
(Colen et al., 2006). CHC inhibition also induced cell
death in colorectal and cervix carcinoma cells, as well as
a decrease in intracellular pH (Sonveaux et al., 2008).
Colen and collaborators used CHC in two glioma cell
lines and in an ex vivo brain slice culture and
demonstrated that lactate efflux inhibition clearly
impaired glioma cell invasion (Colen et al., 2011). 
CHC and DBDS were used in another study with
melanoma cells and ex vivo DB-1 human melanoma
xenografts, in which a great potential to selectively
disturb melanoma cell viability, with a demonstrated
decrease in intracellular pH, which improved the
effectiveness of these chemotherapeutic drugs. These
findings point at MCTs as major pH regulators in
melanoma cells (Wahl et al., 2002). 
More recent studies showed a decrease in lactate
production, accompanied by a decrease in cell
proliferation, migration and invasion capacity upon
lactate efflux inhibition with CHC in glioma (Miranda-
Goncalves et al., 2013) and breast cancer cells (Morais-
Santos et al., 2014) . Importantly, CHC was able to
enhance the effect of temozolamide, a gold standard
drug currently used in the treatment of gliomas
(Miranda-Goncalves et al., 2013).
Inhibition of MCT1/2 with a more specific inhibitor
(AR-C155858) in RAS-transformed fibroblasts inhibited
lactate export, glycolysis rates and tumour growth.
Interestingly, when MCT4 was expressed, cells became
resistant to MCT1/2 inhibition and tumourigenicity was
restored (Le Floch et al., 2011).
The drug lonidamine was used in MCF-7 human
breast cancer cells, promoting a decrease in initial
glucose uptake and lactate formation (Ben-Horin et al.,
1995). However, other authors used the same drug in
glioma cultured tumors and concluded that lonidamine
action also involves inhibition of lactate efflux and
intracellular acidification, suggesting its exploitation for
sensitizing gliomas to radiation, chemotherapy or
hyperthermia (Ben-Yoseph et al., 1998). Additionally, in
neuroblastoma cells, MCT1 inhibition by lonidamine
also promoted intracellular acidification, and consequent
decrease in cell viability, causing cell death by apoptosis,
similarly to CHC (Fang et al., 2006). A more recent
study demonstrated that lonidamine and quercetin were
able to decrease lactate production, cell proliferation,
migration and invasion in breast cancer cells, also
similarly to CHC (Morais-Santos et al., 2014).
Since specificity of MCT inhibition can be limited
when using small molecule compounds, some studies
started to use RNA interference (RNAi) or other
technologies to more accurately study the role of MCTs
in cancer. 
In a glioma cell line, lactate efflux was reduced by
30% for individual silencing of either MCT1 or MCT2,
and by 85% for combined silencing, decreasing
intracellular pH, cell viability and increasing both
apoptosis and necrosis (Mathupala et al., 2004). In
another study, silencing of MCT1 in glycolytic glioma
cells reduced lactate efflux, migration and sensitivity to
CHC (Miranda-Goncalves et al., 2013).
Gallagher and collaborators, by silencing MCT
expression by RNAi, described an interaction between
MCT4 and β1-integrin and investigated the role of
MCT4 knockdown in migration. They found that MCT4
silencing slowed migration and increased focal adhesion
size in epithelial and breast cancer cell lines (Gallagher
et al., 2007, 2009), probably mediated by MCT/CD147
complex disruption, while MCT1 silencing did not alter
these features (Gallagher et al., 2009). 
In a human colon adenocarcinoma cell line,
silencing of either MCT1 plus MCT4 or CD147 reduced
cell glycolytic flux as well as tumour growth (Le Floch
et al., 2011). Furthermore, specific inhibition of MCT1
with siRNA corroborated the results obtained with CHC,
lonidamine and quercetin inhibition, decreasing in vitro
cancer cell aggressiveness in breast cancer cells, by
decreasing proliferation, migration and invasion
(Morais-Santos et al., 2014).
Studies using in vivo models
The well-known MCT inhibitor CHC has also been
used in in vivo models, namely mouse xenografts and
chick chorioallantoic membrane (CAM) models.
In induced intracranial glioma tumours, CHC caused
tumour necrosis and, importantly, control animals did
not demonstrate any adverse neurologic effects during its
administration (Colen et al., 2011). Other authors
reported a reduction in tumour growth and cell
sensitization to radiation, after MCT1 inhibition with
CHC using colorectal and cervical cells injected
intramuscularly in the leg of mice (Sonveaux et al.,
2008). In experiments using human colorectal and breast
cancer cells silenced for MCT expression, injected
subcutaneously in nude mice, MCT4 was pointed out as
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an important link between tumour metabolism and
angiogenesis, mediated by the released lactate, which
stimulates the NF-KB/IL-8 pathway (Vegran et al.,
2011). A recent study using nude mice for prostate
tumour induction, where carbohydrate restriction was
combined with lactate transport inhibition by CHC,
demonstrated that MCT1 inhibition did not have a
significant effect on tumour volume, but was associated
with an increased necrotic fraction (Kim et al., 2012).
Additionally, subcutaneous cervix tumours were treated
with CHC and, unexpectedly, lactate concentration,
necrosis and hypoxic areas were not affected. However,
CHC treatment induced inhibition of glycolysis and
activation of OXPHOS (Pasteur effect), showing that
CHC is able to influence intratumoural distribution of
glucose between hypoxic and non-hypoxic tumour areas
(Busk et al., 2011).
In the chick chorioallantoic membrane (CAM) in
vivo model, treatment with CHC was able to decrease
glioma tumour size, proliferation and the number of
tumour vessels associated with the tumour (Miranda-
Goncalves et al., 2013). 
MCTs as transporters of anticancer compounds
The above described shows the important activity of
MCTs, namely of MCT1 and MCT4, in the proliferation
and aggressiveness of tumour cells. MCTs are thus
important targets in cancer therapy, leading to tumour
regression when inhibited. This is due, mainly, to the
important role of lactic acid for tumour characteristics;
indeed, high levels of lactic acid are associated with poor
prognosis, contributing directly to tumour progression
(Dhup et al, 2012). 
However, other monocarboxylates or mono-
carboxylate derivatives, which are also MCTs substrates,
can have an opposite effect in cancer cells. Actually,
some haloderivatives of monocarboxylic acids like 3-
bromopyruvate (3-BP), dichloroacetate (DCA) and
iodoacetate (IAA), are described as antiglycolytic
agents, and their inhibitory effect in tumours is described
either in in vivo or in vitro systems (Fahim et al., 2003;
Ko et al., 2004; Bonnet et al., 2007).
From this standpoint, overexpression of
monocarboxylic acid transporters can be seen as a
molecular target for cancer therapy, not only due to its
direct effect on tumour growth, but also, in an opposite
way, due to their capacity to mediate the transport of
monocarboxylic acid-related compounds with anticancer
properties.
A major challenge in developing an anticancer drug
is to specifically target cancer cells, avoiding the toxic
side effects in normal tissues. Different compounds
targeting the glycolytic metabolism or signalling
pathways that regulate cellular metabolism have
emerged in the last years. Several of them showed a
promising, selective and significant cytotoxicity to
cancer cells, and pre-clinical and clinical trials to
validate their therapeutic anticancer effect were already
established or are ongoing. Table 1 summarizes some of
these anticancer agents that inhibit the cancer glycolytic
phenotype, their putative molecular targets, mechanism
of action and the current clinical status.
From the antiglycolytic agents listed in Table 1, 3-
BP, DCA and IAA are haloderivatives of
monocarboxylic acids. All these molecules display, at
physiological pH, a hydrophilic nature, requiring a
plasma membrane transporter to reach their intracellular
molecular target(s). There are several reports pointing at
the involvement of some MCT or SMCT family
members in the uptake of these compounds by
mammalian cells (Fishbein et al., 1988; Babu et al.,
6
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Table 1. Therapeutic agents specifically targeting glycolytic metabolism in tumours. Compiled from (Kroemer and Pouyssegur, 2008; Rodriguez-
Enriquez et al., 2009; Tennant et al., 2010; Porporato et al., 2011; Vander Heiden, 2011; Granchi and Minutolo, 2012; Jones and Schulze, 2012).
Agent Molecular target(s) Effect Current clinical status
Phloretin GLUTs Inhibition of glucose uptake Preclinical
Sylibin GLUTs Inhibition of glucose uptake Phase I/ II
2-DG GLUTs HK Inhibition of glucose uptake, Blocks glycolytic flux; ATP depletion Phase I/ II
Lodamine HKII MCTs Blocks glycolytic flux Inhibition of lactate transport Phase II/ III
3-BP HKII GAPDH Alkylating agent Blocks glycolytic flux Dissociates HK II from the mitochondria Preclinical Translational study reported
3PO (and derivatives) PFKFB3 GAPDH Blocks glycolytic flux Preclinical
Iodoacetate GAPDH Alkylating agent Blocks glycolytic flux Preclinical 
TLN232 PKM2 Peptidic inhibitor Phase II
FX11 LDH Blocks glycolytic flux Preclinical
DCA PDK PDK inhibitor Reactivates PDH and redirects  OXPHOS Phase I/ II
glucose metabolism from glycolysis towards
CHC MCT Inhibition of lactate transport
AZD3965 MCT1 Inhibition of lactate transport Phase I/ II
2-DG, 2-deoxyglucose; 3-BP, 3-bromopyruvate; 3PO, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; CHC, α-cyano-4-hydroxycinnamate; DCA,
dichloroacetate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GLUT, glucose transporter; HK, hexokinase; LDH, lactate dehydrogenase;
MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PFKFB3, bifunctional enzyme
phosphofrutokinase2/frutose-2,6-bisphosphatase; PKM2, pyruvate kinase M2.
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2011; Queiros et al., 2012; Birsoy et al., 2013). 
3-bromopyruvate 
3-BP is a pyruvate haloderivative that alkylates
proteins, generally in the -SH group of cysteine residues,
leading to the corresponding loss of functionality.
Several studies have been published, reporting 3-BP
toxic effect on cancer cells, both in vitro and in vivo (Ko
et al., 2001, 2004; Kim et al., 2008; Davidescu et al.,
2012; El Sayed et al., 2012; Icard et al., 2012; Nakano et
al., 2012; Tang et al., 2012), without relevant side
effects. Very recently, a translational study demonstrated
that 3-BP is a powerful and specific anticancer agent in
humans (Ko et al., 2012). 3-BP is known for the ability
to inhibit cancer cell energy metabolism, depleting
cellular ATP and leading to cell death, which could
implicate autophagy (Davidescu et al., 2012), apoptosis
(El Sayed et al., 2012) or necrosis (Bhardwaj et al.,
2010), depending on the tumour type.
One of the main molecular targets of 3-BP is the
glycolytic enzyme hexokinase II (HKII). This HK
isoform is highly expressed in several tumours and is,
similarly to MCTs, upregulated by HIF-1α, favouring
the “Warburg effect” (Wolf et al., 2011). Overexpression
of HKII is related to poor prognosis, as glycolysis is the
primary energy source used by cancer cells to sustain
their uncontrolled cell growth. 3-BP induces a covalent
modification of HKII, likely in cysteine residues, and
dissociates it from the mitochondria, promoting the
release of the apoptosis inducing factor (AIF) and
triggering apoptosis (Chen et al., 2009). However, 3-BP
is a highly reactive alkylating agent and is toxic in
concentrations that are too low to inhibit HKII,
indicating that it may have other targets in cancer cells
(Pereira da Silva et al., 2009). At the mitochondrial
level, it seems to affect not only the energy production
coming from glycolysis, but also mitochondrial
respiration, inducing a whole cell factory ATP depletion
(Ko et al., 2001, 2004). Different reports also point to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
as the prime target for 3-BP (Ganapathy-Kanniappan et
al., 2010, 2013; Tang et al., 2012). GAPDH is a
glycolytic enzyme that catalyses the production of 1,3-
bisphosphoglycerate from glyceraldehyde 3-phosphate
and Pi, with simultaneous reduction of NAD+ to NADH.
Although widely used as housekeeping control in several
assays, since it is constitutively expressed in all tissues,
GAPDH was found to be upregulated in different types
of cancer, in agreement with its function in glycolysis
(Guo et al., 2013). Like other proteins involved in the
Warburg effect, its expression is induced by hypoxic
conditions, in a process dependent of HIF-1α
transcription factor (Higashimura et al., 2011). The
ability of 3-BP to inhibit Histone Deacetylase (HDAC)
isoforms 1 and 3 leading to apoptosis in breast cancer
cell line MCF-7, has also been shown (Thangaraju et al.,
2009). 
The selective uptake of 3-BP by cancer cells could
be the reason for such a specific effect. A first report
revealed the involvement of SMCT1 on 3-BP uptake
(Thangaraju et al., 2009). However, SMCT1 is a tumour
supressor protein found downregulated in most cancer
types (Ganapathy et al., 2008). In opposition, MCT
members, namely MCT1 and MCT4, contribute to the
malignant phenotype of cancer cells and, as already
mentioned, they are upregulated in several tumours
(Pinheiro et al., 2012). Several reports atribute to MCTs
the role of 3-BP transport and it is believed that they
play a crucial role in the specific tumour-induced death
effect of 3-BP. Queirós and collaborators demonstrated
that butyrate pre-treatment of breast cancer cells
upregulates plasma membrane expression of both MCT1
and MCT4 and simultaneously potentiates 3-BP
antitumour activity, clearly indicating an association
between MCT expression and 3-BP effect (Queiros et
al., 2012). More recently, it has been reported that
glutamine starvation also enhanced 3-BP cytotoxicity,
through an increase in MCT1 stability (Cardaci et al.,
2012). Also supporting the role of MCT1 in 3-BP
transport is the inhibitory effect of CHC, which
promoted a decrease in the cytotoxic effect of 3-BP in a
squamous cell carcinoma bearing mouse model
(Matsumoto et al., 2013). Further evidence for 3-BP as a
substrate of MCT1 was given in a genome wide analysis
of a mutated cells library exposed to 3-BP. Massive
parallel sequencing identified MCT1 and its chaperone
CD147 as the two most frequently inactivated genes in
3-BP resistant clones (Birsoy et al., 2013). In the same
work, MCT1 stable expression in a cancer cell line
devoid of MCT1 sensitized it to 3-BP treatment. Overall,
these results indicate a clear role of MCTs in 3-BP
cytotoxic effect, most probably by mediating its entrance
into cancer cells. 
Acetate derivatives: Dichloroacetate and Iodoacetate
Besides pyruvate and its derivatives, MCTs can
mediate the transport of acetate too (Rae et al., 2012).
DCA and IAA are antiglycolytic agents with antitumour
activity that are acetate haloderivatives, being reasonable
to expect that they could also be MCT substrates.
DCA is a compound already in clinical use to treat
patients with mitochondrial deficiencies that develop
lactic acidosis (Stacpoole et al., 1988). The target of
DCA is pyruvate dehydrogenase kinase (PDK), a
regulatory enzyme that phosphorylates and inhibits
pyruvate dehydrogenase (PDH), a component of the
pyruvate dehydrogenase complex (PDC) that catalyses
the decarboxylation of pyruvate to acetyl-CoA, CO2 and
NADH. DCA mimics pyruvate and binds to its binding
site in the N-terminal domain of PDK, inactivating it
(Knoechel et al., 2006), which disrupts the Warburg
effect by switching the glycolytic metabolism towards
mitochondrial oxidative phosphorylation. DCA
treatment reactivates PDH, leading to an increased
entrance of acetyl-CoA in TCA. The aerobic glucose
oxidation in cancer cells increases toxic mitochondrial
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reactive oxygen species (ROS), damaging the
mitochondrial complex I, and depolarizing the
mitochondrial membrane, one of the earliest events in
apoptosis (Heshe et al., 2011). DCA showed relevant
cytotoxic effects in different types of cancers (Granchi
and Minutolo, 2012), and its effect was even more
pronounced in vivo than in vitro (Papandreou et al.,
2011). Its safety in clinical cases has been demonstrated
in patients with congenital or acquired lactic acidosis
treated with DCA. 
It has been reported that DCA must be used in a high
concentration to be effective in cancer treatment
(Stockwin et al., 2010), much higher than that needed to
inactivate PDK (Cooper et al., 1974, Whitehouse et al.,
1974). Babu and collaborators (Babu et al., 2011)
hypothesised that this could be due to the absence of a
transport system, as DCA is ionized and, so, unable to
cross the plasma membrane by simple diffusion. Indeed,
mitoplatin, a dual anticancer agent constituted by one
molecule of cisplatin with two molecules of DCA, is
considerably more cytotoxic than DCA alone, even in
cisplatin resistant cells. The DCA component induces
mitochondrial dysfunction, overcoming cisplatin
resistance, and the increased lipophilicity of the
8
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Fig. 1. Schematic representation of the pivotal role of MCTs in cancer: as lactate exporters to support the metabolic demands of tumours or as targets
for cancer therapy using inhibitory compounds (blue boxes) or mediating the uptake of monocarboxylate analogues with anticancer properties. 3-BP: 3-
Bromopyruvate; CHC: α-cyano-4-hydroxycinnamic acid; DBDS: 4,4-dibenzamidostilbene- 2,2-disulfonate; DCA: dichloroacetate; DIDS: 4,4'-
diisothiocyano-2,2'-stilbenedisulfonic acid; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; HDACs: histone deacetylases; HK: hexokinase; IAA:
iodoacetate; MCT: monocarboxylate transporter; OXPHOS, oxidative phosphorylation; SMCT: sodium monocarboxylate transporter; PDH: pyruvate
dehydrogenase; PDK: pyruvate dehydrogenase kinase.
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molecule allows DCA entrance in the cell (Dhar and
Lippard, 2009). SMCT1 has been identified as
responsible for DCA uptake, with high affinity (Babu et
al., 2011) but it is epigenetically silenced in most tumour
cells (Ganapathy et al., 2005), which could explain why
high DCA concentrations should be used to achieve
cytotoxicity in cancer cells. However, the MCT family
members that are expressed in cancer cells display low
affinity for DCA (Jackson and Halestrap, 1996). To our
knowledge, no further report evidenced MCTs as being
involved in DCA transport in cancer cells. 
Few studies have been done concerning the effect of
the antiglycolytic agent IAA in cancer, at least using in
vivo assays, and even fewer concerning its uptake by
cells. Like 3-BP, IAA is an alkylating agent that reacts
with the -SH group of Cys149 from the active site of
GAPDH (Harris and Walter, 1976; Granchi and
Minutolo, 2012) and it has been shown to target key
enzymes of the pentose phosphate pathway (glucose-6-
phosphate dehydrogenase and 6-phosphogluconate
dehydrogenase), inhibiting the synthesis of cellular
components essential for tumour growth and survival
(Granchi and Minutolo, 2012). Although the anticancer
action mechanism of IAA has not yet been entirely
investigated, the different studies where IAA has been
used showed its potential use as an anticancer agent
(Bhardwaj et al., 2010; Sanchez-Arago and Cuezva,
2011). IAA is an acetate derivative and, like 3-BP or
DCA, it may be transported by MCTs and/or SMCT1.
However, in contrast to the other two compounds, no
reports are published showing these transporters’
influence on IAA activity. The only evidence that
(S)MCTs can be in involved in IAA transport is given in
a report from 1988, where the addition of IAA promoted
the efflux of lactate in human erythrocyte cells (Fishbein
et al., 1988). Further investigation of IAA action in
cancer cells and its transport through the plasma
membrane may be important to develop novel anticancer
therapies.
Final remarks
In conclusion, these data show that MCTs, especially
MCT1 and MCT4 can be of great clinical value for
cancer therapy, as they can be explored either as specific
molecular targets or as drug transporters, opening new
perspectives in cancer therapy (Fig. 1).
On one hand, the efflux of lactate and protons
through monocarboxylic acids transporters allows the
maintenance of cancer cell hyperglycolytic and acid-
resistant phenotype, also creating an environment which
promotes tumour cell invasion and metastization
(Pinheiro et al., 2012). The upregulation of MCT
isoforms 1 and 4, is, therefore, important for cancer
survival, being important potential targets for cancer
therapy. Lactate efflux via MCTs can be blocked using
specific inhibitors or siRNA, leading to tumour
regression. On the other hand, MCTs can behave as
Trojan horses, mediating the transport of anticancer
drugs, resulting in cell death. From the candidate
compounds currently known, 3-BP is the only confirmed
MCT substrate so far, although we cannot exclude the
possibility of MCTs being also involved in DCA and
IAA uptake into cancer cells. Considering the
upregulation of MCTs (the gate) and glycolytic
enzymes/regulators (the targets) in several cancers,
antiglycolytic compounds that are MCT substrates can
be exploited as anticancer agents in the treatment of a
wide range of cancers.  
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